Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3425 - A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung)


08 Oct 2016


Poster Display


Paula Fracasso


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


P.M. Fracasso1, D.J. Freeman2, K. Simonsen3, Y. Shen3, M. Gupta4, A. Comprelli5, J.F. Gainor6, M. Hellmann7, L.Q. Chow8, P.M. Forde9, R. Govindan10, T.P. Reilly11, J. Cassidy5

Author affiliations

  • 1 Group Medical Director, Immuno-oncology/oncology, Exploratory Clinical And Translational Research, Bristol-Myers Squibb, 08540 - Princeton/US
  • 2 Oncology Biomarkers, Bristol-Myers Squibb, 08543 - Princeton/US
  • 3 Biostatistics, Bristol-Myers Squibb, 08543 - Princeton/US
  • 4 Clinical Pharmacology And Pharmacometrics, Bristol-Myers Squibb, 08543 - Princeton/US
  • 5 Oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 6 Department Of Medicine, Massachusetts General Hospital, Boston/US
  • 7 Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 8 Department Of Medicine, Division Of Medical Oncology, University of Washington, Seattle/US
  • 9 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 21287 - Baltimore/US
  • 10 Division Of Oncology, Washington University School of Medicine, St. Louis/US
  • 11 Immuno-oncology, Bristol-Myers Squibb, 08543 - Princeton/US


Abstract 3425


The unprecedented success of the immuno-oncology (I-O) agents, nivolumab and ipilimumab, in several malignancies has resulted in the rapid development of other I-O agents against novel immune targets. Given the potential promise of increased survival, these agents have not followed the traditional phase 2 trial evaluation. FRACTION-Lung is a randomized, open-label, phase 2 trial with an adaptive design that offers patients (pts) with advanced non-small cell lung cancer (NSCLC) expeditious access to early I-O therapies in combination with nivolumab. Based on both preclinical and clinical trial data, combinations of I-O therapies that have potential to produce transformational activity in lung cancer will be selected and offered to pts in a continuous throughput design.

Trial design

Methods: A master protocol defines the overarching framework for this clinical study in which pts with metastatic and/or recurrent NSCLC previously treated with platinum chemotherapy and tyrosine kinase inhibitors (if EGFR mutated or ALK rearranged) are eligible. Based on prior I-O therapy experience and PD-L1 expression, pts will be enrolled into various treatment tracks. Sub-protocols specify the preclinical and preliminary clinical data for new treatment combinations that will be added on a rolling basis. Pts will receive treatment until completion, progression, or toxicity. On progression, pts may enroll into other combination regimens allowing evolution of treatment if needed. An assessment of peripheral blood and tumor biomarkers will enable interrogation of the biological basis for pt response. Primary endpoints are objective response rate, duration of response, and progression-free survival at 24 weeks, with the potential for early stopping; the secondary endpoint is safety. The study is actively enrolling (NCT02750514).

Conclusion: FRACTION-Lung represents an innovative clinical trial that utilizes a rolling, adaptive design with novel I-O therapies. It will accelerate the development and selection of the next generation of transformational I-O combinations for pts with metastatic NSCLC.

Clinical trial identification


Legal entity responsible for the study

Sponsored by Bristol Myers-Squibb


Sponsored by Bristol Myers-Squibb


P.M. Fracasso, D.J. Freeman, K. Simonsen, Y. Shen, A. Comprelli, J. Cassidy: Employee of Bristol-Myers Squibb. M. Gupta: Employed by the study sponsor (Bristol-Myers Squibb) and has stock ownership or options in Bristol-Myers Squibb. J.F. Gainor: Personal fees from Bristol-Myers Squibb, Novartis, Merck, Genentech/Roche, Clovis, Boehringher Ingelheim, and non-financial support from Jounce outside the submitted work. M. Hellmann: Consultant/Advisory Board member for BMS, Merck, Genentech, AZ, and Neon. Research support from BMS. L.Q. Chow: Fees from Astellas, grants, fees & non-financial support from Novartis, grants & fees from BMS, fees & non-financial support from Merck, grants from Eli Lilly/Imclone, OSI Pharma, Genentech, VentiRx, Pfizer, GSK, AZ/MedImmune outside the submitted work. P.M. Forde: Grants from BMS during the conduct of the study, and grants from BMS, Novartis, AstraZeneca, and Kyowa outside the submitted work. R. Govindan: Personal fees from Boehringer Ingelheim, GlaxoSmithKline, Celgene, Roche, Merck, Bayer, Genentech, Clovis Oncology, Helsinn Healthcare, and Pacritinib outside the submitted work. T.P. Reilly: Employee and stockholder of Bristol-Myers Squibb.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings